Paradigm Peptides

Paradigm Peptides is a research compound supplier founded and based in Illinois, historically positioned within the premium tier of the category by emphasizing testing documentation and product breadth over lowest-price competition. At its operating peak, independent vendor reviews describe Paradigm's catalog as one of the more comprehensive in the industry, spanning more than 30 compounds across peptides, SARMs, nootropics, and lab supplies — including BPC-157, TB-500, GHK-Cu, PT-141, Sermorelin, CJC-1295, Ipamorelin, and Epithalon.

The company states its research peptides and SARMs are independently tested to verify authenticity and purity, with the majority of listings claimed to exceed 98% purity and select compounds exceeding 99%, backed by certificates of analysis from independent third-party laboratories. Third-party review aggregators have given the company a middling-to-solid reputation score (roughly 3.8 out of 5 across dozens of reviews), with reviewers generally reporting that products performed as expected, though some noted that batch-specific COA documentation was not always as current or detailed as competitors provide.

Researchers evaluating Paradigm Peptides should be aware of an important operational caveat: multiple industry sources reported reduced operations or a possible shutdown of the original paradigmpeptides.com storefront in late 2025, alongside the emergence of additional similarly named domains (paradigmpeptides.is and paradigmpeptidesllc.com) that may represent rebranding, ownership changes, or unaffiliated copycat sites — researchers should confirm which domain is the current, legitimate operating entity before engaging with the vendor. All products historically offered by Paradigm Peptides were marketed strictly for laboratory research use and explicitly not for human consumption.